## CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to bea) a guide for reporting for authors of RCTs,b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126

URL: http://www.jmir.org/2011/4/e126/

doi: 10.2196/jmir.1923 PMID: 22209829

登录 Google 即可保存进度。了解详情

\*必填

Your name \*

First Last

Shu-Fang Xia

Primary Affiliation (short), City, Country \* University of Toronto, Toronto, Canada

Jiangnan University, Wuxi, China

Your e-mail address \* <a href="mailto:abc@gmail.com">abc@gmail.com</a>

xiashufang@jiangnan.edu.cn

Title of your manuscript \* Provide the (draft) title of your manuscript.

Web-based TangPlan and WeChat Combination to Support Self-Management for Patients with Type 2 Diabetes: Randomized Controlled Trial

Name of your App/Software/Intervention \*

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

TangPlan and WeChat

## Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

## 您的回答

## Language(s) \*

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

Chinese

## URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

您的回答

URL of an image/screenshot (optional)

您的回答

## Accessibility \*

Can an enduser access the intervention presently?

- access is free and open
- access only for special usergroups, not open
- ) access is open to everyone, but requires payment/subscription/in-app purchases
- ) app/intervention no longer accessible
- ) 其他:

#### Primary Medical Indication/Disease/Condition \*

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

#### Diabetes

### Primary Outcomes measured in trial \*

comma-separated list of primary outcomes reported in the trial

#### FBG and HbA1c

#### Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

The secondary outcomes included changes in body weight, BMI, blood pressure and serum lipid profiles.

#### Recommended "Dose" \*

What do the instructions for users say on how often the app should be used?

- Approximately Daily
  - Approximately Weekly
  - Approximately Monthly



- ) "as needed"
- ) 其他:

Approx. Percentage of Users (starters) still using the app as recommended after 3 months *
Inknown / not evaluated
0-10%
0 11-20%
O 21-30%
31-40%
O 41-50%
51-60%
61-70%
O 71%-80%
81-90%
91-100%
○ 其他:
Overall, was the app/intervention effective? *
yes: all primary outcomes were significantly better in intervention group vs control
O partly: SOME primary outcomes were significantly better in intervention group vs control
O no statistically significant difference between control and intervention
O potentially harmful: control was significantly better than intervention in one or more outcomes
O inconclusive: more research is needed
○ 其他:

## Article Preparation Status/Stage \*

At which stage in your article preparation are you currently (at the time you fill in this form)

- not submitted yet in early draft status
- 🔵 not submitted yet in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- ) published
- ) 其他:

## Journal \*

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- ) Journal of Medical Internet Research (JMIR)



- ) JMIR Serious Games
- ) JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- ) 其他:

Is this a full powered effectiveness trial or a pilot/feasibility trial? *
Pilot/feasibility
O Fully powered
Manuscript tracking number *
If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)
O no ms number (yet) / not (yet) submitted to / published in JMIR
● 其他: 30571

## TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *
I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")
• yes
○ 其他:

## 1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容

## Does your paper address subitem 1a-i?\*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Web-based TangPlan ..." in the manuscript title.

 1a-ii) Non-web-based components or important co-interventions in title.

 Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

 1
 2
 3
 4
 5

 subitem not at all important
 O
 O
 O
 O
 O
 essential

 jiii (iii) Non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").
 1
 2
 3
 4
 5

#### Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "the combination of self-designed web-based T2DM management software, TangPlan, and WeChat" in the manuscript title.

## 1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容

#### Does your paper address subitem 1a-iii? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "for Patients with Type 2 Diabetes" in the manuscript title.


## 1b) ABSTRACT: Structured summary of trial design, methods, results, and

#### conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

# 1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



## Does your paper address subitem 1b-i? \*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "This study aimed to examine the effectiveness of the combination of self-designed web-based T2DM management software, TangPlan, and WeChat (TWC) on fasting blood glucose (FBG), glycated hemoglobin (HbA1c), body weight, blood pressure (BP) and lipid profiles in T2DM patients for a 6-month period.", "Participants were recruited from a community healthcare center and randomized into the TWC group or the control group. Participants in the control group received usual care, while the TWC participants received self-management education with the help of TangPlan and WeChat by healthcare professionals, including blood glucose self-monitoring, healthy eating, actively physical exercise, increasing medication compliance, and health education during follow-ups, lectures, or online communication. They were also asked to record and send self-management data to the healthcare professionals by WeChat to obtain timely and effective guidance on diabetes self-management."

## 1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容

### Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Due to the limited number of words in the abstract, we did not mention the human involvement in the abstract, but we have detailed describe the team members composition in the methods section of the main text, "Our multidisciplinary team included healthcare professionals, including the general doctor from the community healthcare center, diabetes specialist nurse, physicians from the department of endocrinology, physicians from the department of rehabilitation, dietitian, and trained diabetes health educator.".

# 1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容


## Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There is no mention in the abstract because of the limitied words, but we have detailed describe the content in the main text. "Potential participants registered in the community who came for clinic visits were identified by trained health workers in one community healthcare center in Wuxi, China. These participants had established a health record in the community healthcare center before January 2020." "All participants confirmed their willingness to participate in screening interviews to assess their eligibility. Our healthcare professionals recorded the participants' relevant information, such as the types of disease, cognitive function, literacy capacity, surgery history in the past 6 months, planned residence time in this city, mobile phone operation ability, etc. After that, based on the inclusion and exclusion criteria, our healthcare professionals selected eligible participants to enroll." "After the participants were finally determined to be eligible to participate in this research, they were notified to go to the community healthcare center at a designated time and digitally randomized in a 1:1 allocation ratio either to a combination of TangPlan and WeChat (TWC) group or usual care alone (control) group. After the results of the grouping were released, the participants were not allowed to switch groups. "

## 1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)




## Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "120 out of 156 participants (77%) completed the 6-month follow-up visit. After the intervention, FBG (6.51 ± 1.66 mmol/L, P = .048), HbA1c (6.87 ± 1.11 %, P < .001), body weight (66.50 ± 9.51 kg, P = .006), systolic BP (SBP, 127.03 ± 8.00mmHg, P = .005), diastolic BP (DBP, 75.25 ± 5.88 mmHg, P = .03), serum low-density lipoprotein cholesterol (LDL-C, 2.50 ± 0.61 mmol/L, P = .006) and total cholesterol (TC, 4.01 ± 0.83 mmol/L, P = .02) in the TWC group were all significantly lower, while serum high-density lipoprotein cholesterol (HDL-C, 1.20 ± 0.25 mmol/L, P = .01) was remarkably higher than those in the control group. Compared with the baseline data, significance was found on the mean change of FBG (95%CI: -0.83 to -0.20; P = .002), HbA1c (95%CI: -1.92 to -1.28; P < .001), body weight (95%CI: -3.13 to -1.68; P < .001), BMI (95%CI: -1.10 to -0.60; P < .001), SBP (95%CI: -7.37 to -3.94; P < .001), DBP (95%CI: -4.52 to -2.33; P < .001), TG (95%CI: -0.16 to -0.03; P = .004), LDL-C (95%CI: -0.54 to -0.30; P < .001) and TC (95%CI: -0.60 to -0.34; P < .001) in the TWC group, but not in the control group (P > .05)." In the main text, "A total of 156 patients were randomized to the TWC group (n = 78) or control group (n = 78); of these, 120 (TWC = 64, control = 56) completed follow-up assessments, yielding a retention rate of 77%."

## 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



## Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is not the negative trial.

## INTRODUCTION

## 2a) In INTRODUCTION: Scientific background and explanation of rationale

## 2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容


#### Does your paper address subitem 2a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "The primary objective of this study was to estimate the impact of the combination of TangPlan and WeChat on blood glucose (BG), glycated hemoglobin (HbA1c), body weight (BW), blood pressure (BP), and lipid profiles in T2DM patients for a 6-month period. "

## 2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.



#### Does your paper address subitem 2a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "However, despite these positive outcomes, the reality is that only a small proportion of patients use apps for diabetes self-management in China. Especially the elderly with diabetes, who account for 80.8% of the total number of diabetic patients [16], are unable to use all kinds of professional apps well, resulting in poor use of diabetes apps for diabetes self-management. Moreover, most of the apps are completely new apps, which are not easy for middle-aged and older Chinese adults to use. Even in the developed countries, diabetic apps usage rate is still low. In Australia, only 8% of diabetic patients use apps to support diabetes self-management [17]. Furthermore, due to the lack of interconnected internetworking systems in different hospitals across China, it is very difficult for healthcare professionals to obtain the patient's diagnosis and treatment records in other hospitals and continuous follow-up information of patients." "WeChat is an extremely popular social application in China and also easy for the elderly to operate. Many researchers have reported the effectiveness of WeChat in chronic diseases management, including diabetes, hypertension, cancer, obesity, stable coronary artery disease, COPD, etc. [18-21]. However, it is also difficult for the healthcare professionals to give diabetic patients detailed selfmanagement advice only based on WeChat, including diet and exercise advice. Therefore, we designed a diabetes management software for the healthcare professionals, TangPlan, which is based on Chinese culture and can be used in conjunction with WeChat to give detailed diabetes self-management advice."

## 2b) In INTRODUCTION: Specific objectives or hypotheses

## Does your paper address CONSORT subitem 2b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "The primary objective of this study was to estimate the impact of the combination of TangPlan and WeChat on blood glucose (BG), glycated hemoglobin (HbA1c), body weight (BW), blood pressure (BP), and lipid profiles in T2DM patients for a 6-month period. "

## METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

#### Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "This study was designed as a 6-month, non-blinded, randomized controlled trial". "After the participants were finally determined to be eligible to participate in this research, they were notified to go to the community healthcare center at a designated time and digitally randomized in a 1:1 allocation ratio either to a combination of TangPlan and WeChat (TWC) group or usual care alone (control) group."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

## Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, we do not have important changes to methods after trial commencement.

## 3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容

## Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, we do not have bug fixes, content changes.

## 4a) Eligibility criteria for participants

## Does your paper address CONSORT subitem 4a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The criteria for inclusion in the study were as follows:

(1) Patients diagnosed with T2DM who met the 1999 WHO diagnostic criteria

(2) Participants with normal cognitive function could read and write, and voluntarily participated in the study

(3) No history of a major surgery during the past 6 months, and no major surgery plan in the next 6 months, and absence of any medication condition that could prevent the patients from walking for 15 minutes to 30 minutes a day

(4) Participants had lived in Wuxi for more than half a year, and were willing to participate in regular follow-ups

(5) Participants or family members living with them could use WeChat proficiently, including sending and receiving messages, voice calls, video calls, etc.

The exclusion criteria for enrollment were as follows:

(1) Diagnosis of T1DM, gestational DM, maturity-onset diabetes of young, or any other types of diabetes

(2) Undergoing hemodialysis for chronic kidney disease

(3) History of any serious heart-related events (such as heart attack or stroke) in the past one year


(4) Patients with pregnancy, or planning for a pregnancy in the next 6 months

(5) Patients with disturbance of consciousness, and mental disorders

(6) Patients participating in other intervention studies".

## 4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.




#### Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "For the first visit of the TWC participants, we added them as WeChat friends, created a WeChat group and ensured that participants could use it proficiently.", "they should send the data to us by WeChat", "participants were also required to keep posted in the WeChat group after taking medications".

## 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely webbased trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.



#### Does your paper address subitem 4a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Potential participants registered in the community who came for clinic visits were identified by trained health workers in one community healthcare center in Wuxi, China. These participants had established a health record in the community healthcare center before January 2020." "All participants confirmed their willingness to participate in screening face-to-face interviews to assess their eligibility. Our healthcare professionals recorded the participants' relevant information, such as the types of disease, cognitive function, literacy capacity, surgery history in the past 6 months, planned residence time in this city, mobile phone operation ability, etc. After that, based on the inclusion and exclusion criteria, our healthcare professionals selected eligible participants to enroll." "After the participants were finally determined to be eligible to participate in this research, they were notified to go to the community healthcare center at a designated time and digitally randomized in a 1:1 allocation ratio either to a combination of TangPlan and WeChat (TWC) group or usual care alone (control) group. After the results of the grouping were released, the participants were not allowed to switch groups."

## 4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.



#### Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Potential participants registered in the community who came for clinic visits were identified by trained health workers in one community healthcare center in Wuxi, China.", "All participants confirmed their willingness to participate in screening interviews to assess their eligibility.", "Prior to participating in the program, informed consent was obtained from each participant to use their data for clinical research."

## 4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "The above indicators were all determined by the laboratory department of the community healthcare center."

## 4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容

## Does your paper address subitem 4b-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We do not have outcomes assessed by online questionaires.

## 4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and								
owners								
Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).								
1	2	3	4	5				
0	0	0	0	$\bigcirc$	essential			
					清除所选内容			
	ns of the d are, this n	ns of the developers, are, this needs to be ript).	ns of the developers, sponsors are, this needs to be declared	ns of the developers, sponsors, and owne are, this needs to be declared in a "Confl ript).	ns of the developers, sponsors, and owners [6] (if are, this needs to be declared in a "Conflict of inteript).			

## Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "The diabetes management software, TangPlan (Figure 1), was designed by our multidisciplinary team using the focus group method, and technical support was provided by Wuxi Wutong Leaf Technology Co., Ltd (Jiangsu, China)."

5-ii) Describe the history/development process								
Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.								
1	2	3	4	5				
0	0	0	0	۲	essential			
					清除所选内容			
	ocess of tl ese will ha	ocess of the applica ese will have an imp	ocess of the application and p ese will have an impact on ad	ocess of the application and previous for ese will have an impact on adoption/use	ocess of the application and previous formative e ese will have an impact on adoption/use rates an			

## Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "The diabetes management software, TangPlan (Figure 1), was designed by our multidisciplinary team using the focus group method, and technical support was provided by Wuxi Wutong Leaf Technology Co., Ltd (Jiangsu, China)."

## 5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容

## Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There is no major revison after the initiation of the trial.

## 5-iv) Quality assurance methods Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable. 1 2 3 4 5 subitem not at all important O O O O O O O essential 清除所选内容

#### Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "The above indicators were all determined by the laboratory department of the community healthcare center and research assistants who did not know the grouping."

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	٢	essential
						清除所选内容

## Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "The diabetes management software, TangPlan (Figure 1)", "The program coached participants in 5 areas, including improving BG self-monitoring, healthy eating, actively physical exercise, increasing medication compliance and health education (Figure 2).", "we used TangPlan to automatically design a personalized weekly diet plan and adjusted some ingredients based on the participant's willingness, and finally printed the diet plan for the participant (Multimedia Appendix 2)."

## 5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容

#### Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The URL of the web-based T2DM management software TangPlan is http://dc.wkdns.cn/admin.php?m=Admin&c=Chart&a=blood&pid=2. TangPlan only needs to log in with password for the first time, and then can log in without password. And staffs from Wuxi Wutong Leaf Technology Co., Ltd help us to maintain the digital preservation of the TangTlan.

#### 5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容


#### Does your paper address subitem 5-vii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "For the first visit of the TWC participants, we added them as WeChat friends, created a WeChat group and ensured that participants could use it proficiently.", "We also told the participants that once they tested BG at home, they should send the data to us by WeChat.", "The participants were asked to keep posted in the WeChat group as once completion of the exercises. For participants who had not kept posted, they would be notified by us on WeChat.", "we conducted interactive health education through the WeChat group. We reminded participants to participate in the interaction on time by sending messages and phone calls, guided participants to express their thoughts and experiences in the WeChat group, praised them for the right approach and pointed out the mistakes."

## 5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].




#### Does your paper address subitem 5-viii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have described in detail in the method of manuscript.

## 5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.




## Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Participants were asked to record self-management data, including BG, meals, physical activity, and medication administration and sent this information to the team by WeChat. We reviewed the participants' data daily, provided dietary recipe once a week, responded to participants and family members' queries and gave personalized feedback during each interaction. We also provided weekly and monthly summaries to participants during follow-ups or through WeChat voice calls during the program."

## 5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).




## Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Our multidisciplinary team included healthcare professionals, including the general doctor from the community healthcare center, diabetes specialist nurse, physicians from the department of endocrinology, physicians from the department of rehabilitation, dietitian, and trained diabetes health educator.", "In the recipe design sub-module, based on the patient's personalized information of patient list module and blood glucose monitoring module, the calorie requirement and the dietary recipe is automatically designed for each patient by a general doctor, a physician from the department of endocrinology, or a dietitian. ", "According to the patient's previous exercise experience, the physicians from the department of endocrinology and rehabilitation select the appropriate physical activity and ascertain the exercise time after careful assessment. ", "The T2DM-related knowledge misunderstandings of each patient are recorded, so that our team members, especially the diabetes specialist nurse and trained diabetes health educators, can correct them during diabetes health education. "

## 5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



#### Does your paper address subitem 5-xi?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "participants were asked to record self-management data, including BG, meals, physical activity, and medication administration and sent this information to the team by WeChat.", " For participants who had not kept posted, they would be notified by us on WeChat."

## 5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容

#### Does your paper address subitem 5-xii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Interactive health education was conducted between team members and participants. First, before the program was launched, our team members evaluated the participant's knowledge of diabetes, medication usage, insulin injection, blood glucose monitoring, diet and exercise, etc. Second, we hold T2DM self-management lectures regularly. Physicians, dietitians, diabetes specialist nurses, and trained diabetes healthcare educators in our team explained the T2DM-related knowledge, including pathogenesis, inducements, and the importance of regular blood glucose monitoring, reasonable diet, medication administration, exercise, and correct blood glucose monitoring methods, etc. We reserved time during each lecture to encourage the participants to ask questions, and team members answered patiently. After that, we hold the T2DM health knowledge competition and encouraged participants to interact with others. We gave rewards to participants with outstanding performance. Finally, we conducted interactive health education through the WeChat group. We reminded participants to participate in the interaction on time by sending messages and phone calls, guided participants to express their thoughts and experiences in the WeChat group, praised them for the right approach and pointed out the mistakes. The focus was to guide participants to realize the importance of regular medication, reasonable diet, proper exercise, and blood glucose monitoring for glycemic control, and to enhance participants' health awareness and self-management capabilities."

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

## Does your paper address CONSORT subitem 6a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Outcome data were collected at baseline and six months after the intervention began. All participants were told to go to the community healthcare center for follow-up at the specified follow-up time and keep a fasting state. The primary outcome measure of the study was the change in FBG and HbA1c levels in the control and TWC groups before and after the intervention. The main secondary outcomes included changes in body weight, BMI, blood pressure and serum lipid profiles. The above indicators were all determined by the laboratory department of the community healthcare center and research assistants who did not know the grouping.", "When the participants arrived at the community healthcare center with a fasting state, their body weight and height were measured. ", " The nurses took venous blood sample, which was for FBG, HbA1c, and serum lipid profiles measurement. After distributing breakfast and instructing the participants to eat, blood was drawn again 2 hours later to measure 2hBG. During the waiting interval of the participant, the blood pressure of the participants was measured after ensuring that the participant was resting for at least 30 min."

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
						清除所选内容

Does your paper address subitem 6a-i? Copy and paste relevant sections from manuscript text

No online questionnaires were used in this study.

6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored									
Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.									
	1	2	3	4	5				
subitem not at all important	0	0	0	0	۲	essential			
						清除所选内容			
Copy and paste relevant sections fro	Does your paper address subitem 6a-ii? Copy and paste relevant sections from manuscript text Yes. we have described in detail in the method section of the manuscript.								
6a-iii) Describe whether, hov was obtained	6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained								
Describe whether, how, and when qua emails, feedback forms, interviews, f			om particip	pants was	obtained	(e.g., through			
	1	2	3	4	5				
subitem not at all important	0	0	0	0	۲	essential			
						清除所选内容			

Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

Yes, "Participants were asked to record self-management data, including BG, meals, physical activity, and medication administration and sent this information to the team by WeChat. We reviewed the participants' data daily, provided dietary recipe once a week, responded to participants and family members' queries and gave personalized feedback during each interaction. We also provided weekly and monthly summaries to participants during follow-ups or through WeChat voice calls during the program. "

## 6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *									
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study									
We don't have any changes to trial outcomes after the trial commenced.									
<b>7a) How sample size was determined</b> NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed									
7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size Describe whether and how expected attrition was taken into account when calculating the sample size.									
	1	2	3	4	5				
subitem not at all important	0	0	0	0	۲	essential			
						清除所选内容			

#### Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "The sample size was calculated based on a completely random design, using the sample size formula for the comparison of the mean of two independent samples. The trial was designed for analysis using two-tailed tests, with type I and II error rates set at 0.05 and 0.1, respectively. We used the difference in the mean HbA1c (0.91%) between the intervention and control groups, along with the standard deviation (1.14 for the intervention group, 1.61 for the control group), from a study about diabetes education and short message service reminders on metabolic control and disease management in patients with type 2 diabetes mellitus [23]. The study was similar to our trial, as both are randomized controlled trials with primary outcomes of HbA1c. The calculations indicated that the total sample size required in each group was 50. Considering the dropout rate of up to 20%, the final sample size was determined to be 60 cases at least in each group."

## 7b) When applicable, explanation of any interim analyses and stopping guidelines

## Does your paper address CONSORT subitem 7b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We didn't have any interim analyses and stopping guidelines.

## 8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

## Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "After the participants were finally determined to be eligible to participate in this research, they were notified to go to the community healthcare center at a designated time and digitally randomized in a 1:1 allocation ratio either to a combination of TangPlan and WeChat (TWC) group or usual care alone (control) group. After the results of the grouping were released, the participants were not allowed to switch groups. "

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Complete random designing.

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "After the participants were finally determined to be eligible to participate in this research, they were notified to go to the community healthcare center at a designated time and digitally randomized in a 1:1 allocation ratio either to a combination of TangPlan and WeChat (TWC) group or usual care alone (control) group. "

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

## Does your paper address CONSORT subitem 10? \*


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. Our multidisciplinary team generated the random allocation sequence and assigned participants to interventions, "based on the inclusion and exclusion criteria, our healthcare professionals selected eligible participants to enroll."

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment

## 11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).



## Does your paper address subitem 11a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This study was designed as a 6-month, non-blinded, randomized controlled trial between April 1, 2020 to October 31, 2020, to examine the efficacy and feasibility of the combination of web-based TangPlan and WeChat on blood glucose control in patients with T2DM."

11a-ii) Discuss e.g., whether p "intervention of interest" and						as the
Informed consent procedures (4a-ii) of participants knew which intervention "comparator".				-		-
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

## Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

## 11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

## Does your paper address CONSORT subitem 11b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "Participants in the control group went to the diabetes clinic of the community healthcare center and received usual care, including medication adjustment, receiving guidance on a healthy and reasonable diet, suggestions on BG self-monitoring and physical activity."

# 12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed


## Does your paper address CONSORT subitem 12a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "The independent sample t-test and Mann-Whitney U-test were used to assess the differences between groups of normally and non-normally distributed data, respectively. Paired t-test and Wilcoxon test were used to test the differences between the control and TWC groups before and after intervention, for normally and non-normally distributed data, respectively. According to the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China" proposed by the Chinese Diabetes Society in 2017, a reasonable HbA1c control target is < 7%. In treatment, HbA1c  $\geq$  7% can be used as an important criterion for the initiation of clinical treatment of type 2 diabetes or the need to adjust the treatment plan. Accordingly, we divided the HbA1c of patients into two categories, HbA1c < 7% was normal, HbA1c  $\geq$  7% was abnormal. McNemar's test was used to determine the impact of intervention on HbA1c levels of the control and TWC groups before and after the intervention, respectively. P < .05 was considered statistically significant."

## 12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).



## Does your paper address subitem 12a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. The missing values of lost subjects used the average value of the indicator for this group instead.

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

## Does your paper address CONSORT subitem 12b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No additional analyses were used in this study.

# X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)



## Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes,"This study was approved by Jiangnan University Medical Ethics Committee (JNU20200312IRB40) and was registered with the Chinese Clinical Trial registry [ChiCTR2000028843]."

## x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容

## Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes," Prior to participating in the program, informed consent was obtained from each participant to use their data for clinical research. " The form contains the purpose, content, duration, frequency of the study, etc.

## X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)



## Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. TangPlan protects the privacy and data security of participant through access control and permission control, patient data transmission and anonymity, redundant storage, and data backup. If the participant has any questions, private chat via WeChat.

## RESULTS

# 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

## Does your paper address CONSORT subitem 13a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "A total of 156 patients were randomized to the TWC group (n = 78) or control group (n = 78); of these, 120 (TWC = 64, control = 56) completed follow-up assessments, yielding a retention rate of 77%."

13b) For each group, losses and exclusions after randomisation, together with reasons

# Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, in the TWC group, 14 participants dropped out, including 3 participants who did not want to use WeChat frequently, 8 participants who found it too difficult to eat strictly according to the dietary recipe, and 3 participants who moved to other cities. In the control group, 22 participants dropped out, including 12 participants who thought that there was no need to continue to participate because their blood glucose was relatively stable, 4 participants who moved to other cities, 3 participants who suffered from serious illnesses, 3 participants thought it was meaningless to participate in this study.

## 13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容

## Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


Yes, the CONSORT flowchart of this study was shown in Figure 3.

## 14a) Dates defining the periods of recruitment and follow-up

## Does your paper address CONSORT subitem 14a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "This study was designed as a 6-month, non-blinded, randomized controlled trial between April 1, 2020 to October 31, 2020."



## Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We did not have critical "secular events".

## 14b) Why the trial ended or was stopped (early)

## Does your paper address CONSORT subitem 14b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The limited funding of our project led to the end of the trial.

## 15) A table showing baseline demographic and clinical characteristics for each

#### group

NPT: When applicable, a description of care providers (case volume, gualification, expertise, etc.) and centers (volume) in each group

## Does your paper address CONSORT subitem 15? \*

Copy and paste relevant sections from the manuscript (include guotes in guotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes,"The baseline characteristics of the participants were demonstrated in Multimedia Appendix 1. 36 (64%) male and 20 (36%) female participants participated in the control group, while 40 (63%) male and 24 (37%) female participants were enrolled in the TWC group. No statistically significant difference in the baseline characteristics, including age (P = .09), education level (P = .65), family monthly income (P = .49), T2DM duration in years (P = .66), body weight (P = .13), BMI (P = .10), HbA1c (P = .84), FBG (P = .35), 2hBG (P = .36), serum lipid profiles, medication (P = .61) and whether there are comorbidities (P = .76) was found between the control and TWC groups (P > .05)"

## 15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容

## Does your paper address subitem 15-i? \*


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, "including age, education level, family monthly income, T2DM duration in years, medication and whether there are comorbidities...in Multimedia Appendix 1"

# 16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

## 16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.



## Does your paper address subitem 16-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We didn't use multiple "denominators".

## 16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

## Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

## 您的回答

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

## Does your paper address CONSORT subitem 17a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The primary and secondary outcomes were reported in Table 1, Table 2, Table 3 and Figure 4.

## 17a-i) Presentation of process outcomes such as metrics of use and intensity of

#### use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

## Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

## Does your paper address CONSORT subitem 17b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We do not have binary outcomes in this trial.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Same as results in the main text.

## 18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

## Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### 您的回答

## 19) All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) Does your paper address CONSORT subitem 19? \* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study There are no harms or unintended effects happened in each group. 19-i) Include privacy breaches, technical problems Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2]. 1 2 3 5 4 subitem not at all important essential 清除所选内容

## Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There aren't privacy breaches, technical problems happened.

# 19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

## Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

## 您的回答

## DISCUSSION

# 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summar outcomes and process outcomes (us		swers sug	igested by	the data,	starting v	vith primary
	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容

## Does your paper address subitem 22-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This study assessed the effectiveness of the combination of web-based TangPlan software and WeChat app to improve glycemic control (decrease in HbA1c levels and blood glucose levels), and serum lipid profiles (decline in TG, LDL-C and TC, increase in HDL-C), as well as reducing body weight in T2DM patients after a duration of 6 months of the program. Patients who used the TangPlan and WeChat-based intervention for 6 months reduced their HbA1c levels by 1.60%, FBG by 0.51 mmol/L, body weight by 2.40 kg, BMI by 0.85 kg/m2, TG by 0.09mmol/L, LDL-C by 0.42 mmol/L, and TC by 0.47 mmol/L, and increased HDL-C levels by 0.05 mmol/L."

## 22-ii) Highlight unanswered new questions, suggest future research Highlight unanswered new questions, suggest future research.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

## Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

## 您的回答

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

## 20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						清除所选内容


## Does your paper address subitem 20-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"One of the limitations of the study was that the occurrence and progression of diabetes complications were not evaluated after the intervention. In addition, the program was performed for a short duration, and we did not independently quantify the influence of other behaviors and lifestyles on glycemic control. The loss of data during follow-up also limited the scope of the study. Future studies with a larger sample with better control will be able to further determine the effectiveness of the program."

## 21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial



## Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Compared to the usual care for T2DM patients, combination of TangPlan and WeChat was effective in improving glycemic control (decrease in HbA1c levels and blood glucose levels), and serum lipid profiles, as well as reducing body weight in T2DM patients."

## 21-ii) Discuss if there were elements in the RCT that would be different in a

## routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.



## Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

您的回答

## OTHER INFORMATION

23) Registration number and name of trial registry

## Does your paper address CONSORT subitem 23? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Chinese Clinical Trial Registry ChiCTR2000028843."

## 24) Where the full trial protocol can be accessed, if available

## Does your paper address CONSORT subitem 24?\*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have given the detailed description in the methods section of the main text to provide the full trial protocol.

# 25) Sources of funding and other support (such as supply of drugs), role of funders

## Does your paper address CONSORT subitem 25? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study was supported by the Wuxi Science and Technology Development Fund (grant number: CSE31N1625).

X27) Conflicts of Interest (not a CONSORT item)

identical with the developers/sponso				thors/eval	luators are	elation of the distinct from or
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address suk Copy and paste relevant sections fror indicate direct quotes from your man information not in the ms, or briefly e 您的回答	n the mar uscript), c	nuscript (ir or elaborat	e on this it	tem by pro	viding add	litional
About the CONSORT EHEAL	.TH che	ecklist				
As a result of using this chec	klist, die	d you m	ake cha	nges in <sup>•</sup>	your ma	nuscript? *
🔘 yes, major changes						
yes, minor changes						
O no						

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript \*

We spent three days going through the checklist.

As a result of using this checklist, do	vou think vou	ur manuscript	t has improved? *
	,		

ves
,

) no


) 其他:

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document

• yes	
O no	
○ 其他:	
	清除所选内容

Any other comments or questions on CONSORT EHEALTH

您的回答



## Final step: Click submit !

Click submit so we have your answers in our database!

提交

清除表单内容

切勿通过 Google 表单提交密码。

此内容不是由 Google 所创建, Google 不对其作任何担保。 举报滥用行为 - 服务条款 - 隐私权政策

## Google 表单